BODY TEMPERATURE LOWERING AGENT, BODY TEMPERATURE ELEVATION SUPPRESSOR, FOOD COMPOSITION FOR LOWERING BODY TEMPERATURE,AND FOOD COMPOSITION FOR SUPPRESSING BODY TEMPERATURE ELEVATION
A body temperature lowering agent, a body temperature elevation suppressor, a food composition for lowering body temperature, and a food composition for suppressing body temperature elevation containing at least one substance selected from the group consisting of orotic acid, a derivative thereof, and a salt of the orotic acid or the derivative as an active ingredient.
NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY (Japon)
DAICO MFG CO., LTD. (Japon)
Inventeur(s)
Kumada, Hiroaki
Kitamura, Naoyuki
Nakamura, Tetsuyuki
Ikeda, Takeshi
Abrégé
The purpose is to prevent the irradiation beam from leaking between the beam irradiation port of the radiation therapy device and the patient affected area that is the target of the emitted irradiation beam, a radiation shielding jig comprising a tare filled with shielding material particles; the tare is made of a resin fabric and has a hollow three-dimensional shape with a radiation pathway portion, the shielding material particles comprising a mixture of sintered particles having a predetermined particle diameter with radiation shielding performance and resin particles having a predetermined particle diameter.
NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY (Japon)
DAICO MFG CO., LTD. (Japon)
Inventeur(s)
Kumada, Hiroaki
Kitamura, Naoyuki
Nakamura, Tetsuyuki
Ikeda, Takeshi
Abrégé
The purpose is to prevent the irradiation beam from leaking between the beam irradiation port of the radiation therapy device and the patient affected area that is the target of the emitted irradiation beam, a radiation shielding jig comprising a tare filled with shielding material particles; the tare is made of a resin fabric and has a hollow three-dimensional shape with a radiation pathway portion, the shielding material particles comprising a mixture of sintered particles having a predetermined particle diameter with radiation shielding performance and resin particles having a predetermined particle diameter.
4.
MICROBIAL STRAIN, PROTEIN, AND METHOD FOR PRODUCING GALLIC ACID USING MICROBIAL STRAIN OR PROTEIN
The purpose of the present technology is to provide: a protein that has a protocatechuic acid 5-position oxidizing activity and can efficiently generate gallic acid from protocatechuic acid; and a microbial strain that expresses said protein. In the present invention, the use of a protocatechuic acid 5-position oxidizing enzyme derived from Comamonas microbes or a protein having at least 70% identity with the amino acid sequence of said protocatechuic acid 5-position oxidizing enzyme allows efficient production of gallic acid from protocatechuic acid. Gallic acid can be produced from protocatechuic acid as a result of fermentation using a microbial strain into which a gene that codes for said enzyme has been introduced.
The purpose of the present invention is to provide a novel nucleic acid construct that induces antibody production. The present invention provides a nucleic acid construct that induces antibody production against a target protein, the nucleic acid construct including a polynucleotide that codes for at least two types of T cell epitopes and a polynucleotide that codes for one or more types of B cell epitopes for the target protein. The present invention makes it possible to powerfully induce antibodies against a target protein within the body of a subject, making it possible not only to induce antibody production against exogenous antigens such as bacteria and viruses but also to induce antibody production against proteins produced within the body of the self.
C12N 15/40 - Protéines de virus à ARN, p.ex. flavivirus
C12N 15/45 - Paramyxoviridae, p.ex. virus de la rougeole, virus des oreillons, virus de la maladie de Newcastle, virus de la maladie de Carré, virus de la peste bovine, virus respiratoires syncytiaux
C12N 15/50 - Coronaviridae, p.ex. virus de la bronchite infectieuse, virus de la gastro-entérite transmissible
6.
PRODUCTION METHOD FOR MICROFIBRILLATED CELLULOSE MOLDED ARTICLE, AND MICROFIBRILLATED CELLULOSE MOLDED ARTICLE
This method is for producing a microfibrillated cellulose molded article formed of a microfibrillated cellulose and a phenolic resin. The method for producing a microfibrillated cellulose molded article comprises: a step for preparing a first preliminary molded sheet formed of a microfibrillated cellulose and 0-10 mass% of water; a step for obtaining a second preliminary molded sheet by exposing the first preliminary molded sheet to water for at least one hour to swell the sheet; a step for obtaining a third preliminary molded sheet by replacing the water contained in the second preliminary molded sheet with a solution containing a phenolic resin having a weight-average molecular weight of at most 1000; a step for drying the obtained third preliminary molded sheet; and a step for thermally pressing the dried third preliminary molded sheet by applying a pressure of 1-10 MPa to the sheet in the thickness direction at a temperature of 120-200°C.
D21H 19/24 - Couches sans pigments appliquées sous une forme autre que la solution aqueuse définie dans le groupe comprenant des composés macromoléculaires obtenus par des réactions autres que celles faisant intervenir uniquement des liaisons non saturées carbone-carbone
D21H 11/18 - Fibres hautement hydratées, gonflées ou aptes à être fibrillées
7.
APPARATUS USED TO DETECT OR STIMULATE ACTIVITY OF NERVE TISSUE
This apparatus (1) comprises at least one intravascular device (10), (20) that is disposed in a blood vessel of an organism and that is equipped with at least one electrode (11), (12), (21), (22) for detecting or stimulating the activity of nerve tissue positioned outside the blood vessel nearby, the electrodes (11), (12), (21), (22) being provided on a wire member.
A61B 5/293 - Détection, mesure ou enregistrement de signaux bioélectriques ou biomagnétiques du corps ou de parties de celui-ci Électrodes bioélectriques à cet effet spécialement adaptées à des utilisations particulières pour l’électroencéphalographie [EEG] invasives
A61B 5/00 - Mesure servant à établir un diagnostic ; Identification des individus
8.
COMPOSITION CONTAINING BOROHYDRIDE SHEET AND CARRIER, AND HYDROGEN RELEASE METHOD USING SAME
The purpose of the present invention is to provide: a composition which is capable of efficiently releasing hydrogen; and a hydrogen release method. The above are achieved by means of a composition which contains a borohydride sheet and a carrier at a volume ratio of 1:0.1 to 100 so that the transmittance of ultraviolet light is more than 0% but less than 100%.
C01B 3/00 - Hydrogène; Mélanges gazeux contenant de l'hydrogène; Séparation de l'hydrogène à partir de mélanges en contenant; Purification de l'hydrogène
C01B 6/00 - Hydrures de métaux; Monoborane ou diborane; Leurs complexes d'addition
C01B 6/11 - Préparation à partir de bore ou de composés inorganiques contenant du bore et de l'oxygène
A secondary battery of the present disclosure includes a positive electrode, an electrolyte layer, a negative electrode current collector, and metallic lithium as a negative electrode active material that is deposited between the electrolyte layer and the negative electrode current collector by charging, an intermediate layer is present between the electrolyte layer and the negative electrode current collector, and the intermediate layer contains hydrogen boride.
The purpose of the present invention is to provide a pharmaceutical composition and the like for treating or preventing inflammation caused by Acanthamoeba. Specifically provided are a pharmaceutical composition for treating or preventing inflammation caused by Acanthamoeba that contains a composite formed by joining lysozyme and chitosan, an antiprotozoal composition that contains a composite formed by joining lysozyme and chitosan, an anti-attachment agent for Acanthamoeba that contains a composite formed by joining lysozyme and chitosan, and the like.
A61K 47/61 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p.ex. les supports ou les additifs inertes; Agents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p.ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique macromoléculaire, p.ex. une molécule oligomérique, polymérique ou dendrimérique le composé organique macromoléculaire étant un polysaccharide ou l’un de ses dérivés
The present invention provides a method for producing natural polymer microspheres, the method including: adding a solution containing a natural polymer (e.g., an aqueous fibroin solution) to an organic solvent, the organic solvent having a surfactant dissolved therein, and homogenizing the resulting mixed solution to generate a natural polymer colloidal suspension; and adding the natural polymer colloidal suspension to an alcohol having 3 or more carbon atoms to form natural polymer microspheres.
A contact lens-shaped intraocular lighting device comprising: a contact lens including a dome-shaped first region that is provided in a central portion and through which light is transmitted, a ring-shaped second region that extends outward in a radial direction from an outer peripheral portion of the first region, and a ring-shaped third region that extends outward in the radial direction from an outer peripheral portion of the second region and is provided to be in contact with the sclera; and a lighting unit that is provided in the second region of the contact lens, adjusts refraction or diffusion of light provided from a light source, and emits the light into the eye.
NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY (Japon)
UNIVERSITY OF TSUKUBA (Japon)
Inventeur(s)
Nosato, Hirokazu
Kochi, Yuta
Sakanashi, Hidenori
Murakawa, Masahiro
Ikeda, Atsushi
Abrégé
An endoscopic diagnosis support method whereby an examined area and an unexamined area can be clearly discriminated. After a preparatory step of an observation canvas is performed in advance, a frame marking step, a key point calculation step, a preceding and following frame displacement amount calculation step, a preceding and following frame marking step are executed to thereby perform observation recording. In an image diagnosis support step IDS, support is performed such that the existence of a lesion is diagnosed in an organ on the basis of a plurality of position data marked with respect to a plurality of frames in the observation canvas data and an endoscopic image in the plural frames.
G16H 50/20 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicales; TIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour le diagnostic assisté par ordinateur, p.ex. basé sur des systèmes experts médicaux
G06V 10/44 - Extraction de caractéristiques locales par analyse des parties du motif, p.ex. par détection d’arêtes, de contours, de boucles, d’angles, de barres ou d’intersections; Analyse de connectivité, p.ex. de composantes connectées
G06T 7/73 - Détermination de la position ou de l'orientation des objets ou des caméras utilisant des procédés basés sur les caractéristiques
A61B 1/05 - Instruments pour procéder à l'examen médical de l'intérieur des cavités ou des conduits du corps par inspection visuelle ou photographique, p.ex. endoscopes; Dispositions pour l'éclairage dans ces instruments combinés avec des dispositifs photographiques ou de télévision caractérisés par le fait que le capteur d'images, p.ex. l'appareil photographique, est placé dans la partie de l'extrémité distale
G16H 30/40 - TIC spécialement adaptées au maniement ou au traitement d’images médicales pour le traitement d’images médicales, p.ex. l’édition
G06V 10/764 - Dispositions pour la reconnaissance ou la compréhension d’images ou de vidéos utilisant la reconnaissance de formes ou l’apprentissage automatique utilisant la classification, p.ex. des objets vidéo
A61B 1/00 - Instruments pour procéder à l'examen médical de l'intérieur des cavités ou des conduits du corps par inspection visuelle ou photographique, p.ex. endoscopes; Dispositions pour l'éclairage dans ces instruments
14.
ORGAN DEFORMATION ESTIMATION DEVICE, TREATMENT DEVICE, TREATMENT ASSISTANCE DEVICE, ORGAN DEFORMATION ESTIMATION METHOD, AND PROGRAM
This organ deformation estimation device is provided with: a three-dimensional model acquisition unit which acquires a three-dimensional model that shows the shape of an organ, the three-dimensional model being generated on the basis of a three-dimensional image of the organ which has been captured previously before the implementation of a treatment; a captured image acquisition unit which acquires a captured image that is an image of the inside of the organ which has been captured during the process of the treatment; a partial image extraction unit which extracts a partial image from the three-dimensional image; an alignment unit which performs the alignment of the captured image with the partial image; a target position calculation unit which calculates a target position on the basis of the result of the alignment; and a displacement estimation unit which estimates the deformation of the organ during the process of the treatment by deforming the three-dimensional model on the basis of a three-dimensional simulation in such a manner that the position of a part corresponding to the inside among parts constituting the three-dimensional model is displaced to the target position.
A non-transitory computer-readable recording medium has stored therein a program that causes a computer to execute a process, the process including acquiring movie data including a plurality of consecutive frames calculating first likelihood of a class of the movie data by inputting the acquired movie data to a trained model, calculating an optical flow indicating movement of an area included in the movie data, based on the movie data generating occluded movie data by setting an occluded area in each of the frames included in the movie data, based on the optical flow, calculating second likelihood of a class of the occluded movie data by inputting the occluded movie data to the model identifying an area that affects identification of the class among areas in the movie data, based on the first likelihood and the second likelihood and displaying the identified area that affects identification of the class.
G06V 20/40 - RECONNAISSANCE OU COMPRÉHENSION D’IMAGES OU DE VIDÉOS Éléments spécifiques à la scène dans le contenu vidéo
G06V 10/774 - Dispositions pour la reconnaissance ou la compréhension d’images ou de vidéos utilisant la reconnaissance de formes ou l’apprentissage automatique utilisant l’intégration et la réduction de données, p.ex. analyse en composantes principales [PCA] ou analyse en composantes indépendantes [ ICA] ou cartes auto-organisatrices [SOM]; Séparation aveugle de source méthodes de Bootstrap, p.ex. "bagging” ou “boosting”
G06V 10/82 - Dispositions pour la reconnaissance ou la compréhension d’images ou de vidéos utilisant la reconnaissance de formes ou l’apprentissage automatique utilisant les réseaux neuronaux
16.
INFORMATION PROCESSING METHOD, INFORMATION PROCESSING SYSTEM, AND COMPUTER PROGRAM
The present invention provides an information processing method, an information processing system, and a computer program. According to the present invention, a computer executes processing that: acquires respective first intermediate representations from a plurality of devices, the first intermediate representations being obtained by applying an intermediate representation conversion function to first data used individually at the devices; acquires respective second intermediate representations from the plurality of devices, the second intermediate representations being obtained by applying the intermediate representation conversion function to second data used in common at the devices; adjusts a parameter for an integrated representation conversion function to minimize the difference in integrated representations obtained by applying the integrated representation conversion function to each of the respective second intermediate representations acquired from the devices; and, on the basis of each of the respective first intermediate representations acquired from the devices and the integrated representation conversion function after adjustment of the parameter, derives a device difference correction function for correcting the device difference between the plurality of devices.
An objective of the present invention is to provide a self-assembled polymer micelle-type ornithine donor, which has high bioavailability, low toxicity, and high therapeutic effectiveness, even when provided by oral administration. Another objective of the present invention is to provide a self-assembled polymer micelle-type ornithine donor which is effective in preventing or treating hepatic disorders. In order to achieve the above objectives, an acyl group is introduced into the primary amino group in the side chain of an ornithine unit in the poly(ornithine) segment of poly(ethylene glycol)-b-poly(ornithine), which spontaneously forms polymer micelles without polyion complex formation.
To stably support a user before and after posture transition between a standing position and a sitting position by suppressing forward and backward movement of a position of the center of gravity of a user without power supply with a simple configuration. A stable support mechanism includes a base, a support structure mounted on the base, the support structure being configured to be capable of translational movement along a first axis in a plane horizontal to the base, the support structure being configured to be capable of changing a posture between a first position and a second position in a plane perpendicular to the base, and a link having a fixed length, one end of the link being connected to the base, the other end of the link being connected to the support structure, the link being configured to guide the support structure in a direction along the first axis along with changing the posture of the support structure.
Biomarkers for detecting cognitive dysfunction diseases and methods for detecting cognitive dysfunction diseases using the biomarkers are provided. A method for detecting cognitive dysfunction diseases comprising measuring one or more biomarkers for detecting cognitive dysfunction diseases selected from the following (a), (b), and (c) in a biological sample simultaneously or separately: (a) a biomarker for detecting cognitive dysfunction diseases consisting of an intact protein of apolipoprotein A1 comprising the amino acid sequence represented by SEQ ID NO:1 or a partial peptide thereof; (b) a biomarker for detecting cognitive dysfunction diseases consisting of an intact protein of transthyretin comprising the amino acid sequence represented by SEQ ID NO:2 or a partial peptide thereof; and (c) a biomarker for detecting cognitive dysfunction diseases consisting of an intact protein of complement C3 comprising the amino acid sequence represented by SEQ ID NO:3 or a partial peptide thereof.
G01N 33/68 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir des protéines, peptides ou amino-acides
C07K 14/47 - Peptides ayant plus de 20 amino-acides; Gastrines; Somatostatines; Mélanotropines; Leurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
20.
FEATURE AMOUNT SELECTION DEVICE, FEATURE AMOUNT SELECTION METHOD, AND PROGRAM
A feature amount selection device includes a feature amount data acquisition unit that acquires feature amount data including a set of values of a plurality of feature amounts for a sample, for each of a plurality of the samples, a principal component analysis unit that performs, on the feature amount data, principal component analysis in a sample space that is a collection of the plurality of feature amounts of a set of values for each of the plurality of the samples of the feature amounts, and a feature amount selection unit that selects a feature amount from among the plurality of the feature amounts based on a result of the principal component analysis performed by the principal component analysis unit.
A method for reconstructing an interior CT image in which a region of interest in an object is irradiated with X-rays and an image of the region of interest in a cross section of the object is reconstructed, wherein the method includes: a projection data acquisition step in which a plurality of pieces of projection data are acquired for an occasion on which the region of interest of the object is irradiated with X-rays in a predetermined angular range in the circumferential direction of the object; and an image calculation step in which when matrices holding pixel information for an occasion on which X-rays pass through a cross section of the object in accordance with the irradiation angle serve as projection calculation matrices, a vector in which the plurality of pieces of projection data are arranged is denoted by b, a matrix in which a plurality of the projection calculation matrices corresponding to the projection data are arranged is denoted by A, and a vector in which the image values of the cross section of the object are arranged is denoted by x, Ax = b is solved under prior information C and an image of the region of interest is determined, said prior information C being the sum of the image values of an image of the cross section of the object.
A secure computation system comprising secure computation server apparatuses, each of which comprises: a discriminant share generation part that computes discriminant shares configured so that an index relating to an input corresponds to a specific value from shares representing the index relating to the input and possible combinations of index shares of an array; a combination configuration part that configures a combination of shares of an element in the array and the discriminant shares for all possible combinations of indices of the array; a shuffle part that shuffles the combinations; a reconstruction part that reconstructs the discriminant shares in the shuffled combinations; and a selection part that selects shares of an element in the array in the combinations where the reconstructed value is the specific value.
G06F 21/57 - Certification ou préservation de plates-formes informatiques fiables, p.ex. démarrages ou arrêts sécurisés, suivis de version, contrôles de logiciel système, mises à jour sécurisées ou évaluation de vulnérabilité
An image display device displays a stereoscopic image by using a parallax barrier method and includes a transmissive image display surface on which images of left-eye image data and right-eye image data are alternately displayed; an image forming unit including optical members having strip-shaped patterns with optical properties arranged on a surface located on a back surface side of the image display surface; and strip-shaped light sources arranged on an illumination arrangement surface, which is a surface located on a back surface side of the image forming unit, and configured to irradiate the image display surface with illumination light. A slit area of the parallax barrier method is formed by an image obtained by forming an image of the illumination light from the strip-shaped light sources on the back surface side of the image display surface by using the optical members of the image forming unit.
H04N 13/312 - Reproducteurs d’images pour visionnement sans avoir recours à des lunettes spéciales, c. à d. utilisant des affichages autostéréoscopiques utilisant des barrières de parallaxe les barrières de parallaxe étant situées derrière l’affichage, p.ex. entre la source de rétroéclairage et le modulateur spatial de lumière [MSL]
H04N 13/305 - Reproducteurs d’images pour visionnement sans avoir recours à des lunettes spéciales, c. à d. utilisant des affichages autostéréoscopiques utilisant des lentilles lenticulaires, p.ex. dispositions de lentilles cylindriques
H04N 13/315 - Reproducteurs d’images pour visionnement sans avoir recours à des lunettes spéciales, c. à d. utilisant des affichages autostéréoscopiques utilisant des barrières de parallaxe les barrières de parallaxe variant dans le temps
24.
GENE INDUCING DIFFERENTIATION INTO FAST MUSCLE FIBERS, COMPOSITION FOR INDUCING DIFFERENTIATION INTO FAST MUSCLE FIBERS, METHOD FOR INDUCING DIFFERENTIATION INTO FAST MUSCLE FIBERS, COMPOSITION FOR INHIBITING DIFFERENTIATION INTO FAST MUSCLE FIBERS, METHOD FOR INHIBITING DIFFERENTIATION INTO FAST MUSCLE FIBERS, METHOD FOR PRODUCING MUSCLE TISSUE AND METHOD FOR PRODUCING EDIBLE MEAT
Provided are: a gene inducing differentiation into fast muscle fibers, said gene being capable of increasing or suppressing the ratio of fast muscle fibers in a muscle tissue and preventing or restoring muscle weakness caused by, for example, aging, injuries or diseases, etc.; a composition for inducing differentiation into fast muscle fibers; a method for inducing differentiation into fast muscle fibers; a method for producing a muscle tissue; and a method for producing an edible meat. A gene inducing differentiation into fast muscle fibers, said gene including a gene encoding a fast muscle fiber differentiation inducing factor comprising any of proteins MafA, MafB and c-Maf; and a composition for inducing differentiation into fast muscle fibers, a method for inducing differentiation into fast muscle fibers, a composition for inhibiting differentiation into fast muscle fibers, a method for inhibiting differentiation into fast muscle fibers, a method for producing a muscle tissue and a method for producing an edible meat, each mainly using the aforesaid gene.
A61K 38/17 - Peptides ayant plus de 20 amino-acides; Gastrines; Somatostatines; Mélanotropines; Leurs dérivés provenant d'humains
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiques; Thérapie génique
A61P 21/00 - Médicaments pour le traitement des troubles du système musculaire ou neuromusculaire
C12N 5/077 - Cellules mésenchymateuses, p.ex. cellules osseuses, cellules de cartilage, cellules stromales médulaires, cellules adipeuses ou cellules musculaires
C12N 7/01 - Virus, p.ex. bactériophages, modifiés par l'introduction de matériel génétique étranger
The purpose of the present invention is to provide a volatile material monitoring system that can accurately acquire the concentration of a volatile material, e.g., ethanol, in an incubator and thereby enable suitable management of the influence exercised by the volatile material on the health of a pediatric patient. The volatile material monitoring system comprises: one or a plurality of sensors (14a, 14b, 14c) disposed in an incubator (1) comprising a housing compartment (101) having a temperature- and humidity-regulatable interior in order to house a pediatric patient (X), wherein the sensor or sensors detect the concentration of a volatile material used due to medical intervention on a pediatric patient (X) in the housing compartment (101); and an estimation unit (161) that estimates, on the basis of the volatile matter concentration detected by the sensors (14a, 14b, 14c), the volatile matter blood concentration in the blood of the pediatric patient (X).
The present invention removes volatile substances from air in an incubator. A purification device (120) includes: an air intake part (121b) for taking in air; a suction part (125) for sucking the air; a second removal part (126) for removing volatile substances, which are substances used in medical intervention on an infant patient, from the air sucked by the suction part (125); and an exhaust part (122b) for exhausting the air from which the volatile substances have been removed by the second removal part (126).
The purpose of the present invention is to avoid the accidental exposure of an infant patient in an infant incubator to a volatile substance. This infant incubator (3) is provided with: a housing chamber (101) in which an infant patient (X) can be housed; and a removal section (134) for removing a volatile substance from air in the housing chamber (101).
F24F 7/003 - Ventilation combinée avec le nettoyage de l'air
F24F 8/158 - Traitement, p.ex. purification, de l'air fourni aux locaux de résidence ou de travail des êtres humains autrement que par chauffage, refroidissement, humidification ou séchage par séparation, p.ex. par filtrage par des moyens chimiques utilisant du charbon actif
28.
VOLATILE SUBSTANCE REMOVAL APPARATUS AND VOLATILE SUBSTANCE REMOVAL METHOD
Provided is a volatile substance removal apparatus capable of sufficiently removing volatile substances such as ethanol floating around a child patient in an incubator. The volatile substance removal apparatus (110, 210, 110A) comprises: a suction unit (115) for suctioning air inside a storage chamber (101) from an intake unit (111c); a removal unit (114, 116) for removing volatile substances contained in the air; an exhaust unit (111d) for exhausting the air from which the volatile substances have been removed by the removal unit (114, 116); and a guide unit (112, 212) for guiding air to the intake unit (111c).
[Object] Provided is a method of producing a nerve fascicle including efficiently extending axons of neural cells.
[Object] Provided is a method of producing a nerve fascicle including efficiently extending axons of neural cells.
[Solution] Neural cells are cultivated in the presence of feeder cells including at least one type of cells selected from the group consisting of vascular component cells, perivascular cells, and oligodendrocytes.
A61L 27/36 - Matériaux pour prothèses ou pour revêtement de prothèses contenant des constituants de constitution indéterminée ou leurs produits réactionnels
C12N 5/071 - Cellules ou tissus de vertébrés, p.ex. cellules humaines ou tissus humains
An imaging lighting instrument for an operation is disposed in a space between an operator's head and a patient, thereby configuring a multi-viewpoint video capturing device for a surgical operation in which blocking of a light by the operator's head or body and appearance of the head in a video are avoided. The imaging lighting instrument includes a plurality of cameras and a plurality of lights attached to a hollow ring-shaped or arc-shaped housing made of a wire member of a finite length, which is devised so as not to interfere with the visual field or work of the operator. Furthermore, the multi-viewpoint video capturing device is configured to have a function of estimating the context of the plurality of cameras and make it possible to perform operation support/recording of a direct-view surgical operation by using a multi-viewpoint video by adding a video information processing function for selecting a camera video in which an operators' hand or surgical instruments less appear in an image.
A61B 90/00 - Instruments, outillage ou accessoires spécialement adaptés à la chirurgie ou au diagnostic non couverts par l'un des groupes , p.ex. pour le traitement de la luxation ou pour la protection de bords de blessures
A rocking device includes: a seat which supports a body of a user; a motor which rotates a rotation shaft in a first rotation direction and in a second rotation direction that is a rotation direction opposite to the first rotation direction, and thereby supplies motive power for rocking the seat via a gear attached to the rotation shaft; and a controller which controls rocking of the seat via the motor. The seat is configured to make a first motion of moving in a first movement direction, in accordance with rotation of the rotation shaft in the first rotation direction, and make a second motion of moving in a second movement direction, in accordance with rotation of the rotation shaft in the second rotation direction. The controller is configured to control rocking of the seat such that a prescribed stopped period is provided between the first motion and second motion.
An information processing apparatus acquires an image; generates a shielding image in which a part of an area included in an area of the acquired image has been shielded; calculates, by inputting the image to a first model that has been trained, first likelihood of the target object included in the image; calculates, by inputting the shielding image to a second model that calculates an approximation value of likelihood of the target object included in the image when the image is input, second likelihood corresponding to the approximation value of the likelihood of the target object included in the shielding image; specifies, based on the first likelihood and the second likelihood, an area that affects discrimination of the class and that is included in the area of the image; and displays the specified area that affects discrimination of the class.
G06V 10/36 - Utilisation d’un opérateur local, c. à d. des moyens pour opérer sur des points d’image situés dans la proximité d’un point donné; Opérations de filtrage locales non linéaires, p.ex. filtrage médian
G06V 10/764 - Dispositions pour la reconnaissance ou la compréhension d’images ou de vidéos utilisant la reconnaissance de formes ou l’apprentissage automatique utilisant la classification, p.ex. des objets vidéo
NATIONAL UNIVERSITY CORPORATION KUMAMOTO UNIVERSITY (Japon)
UNIVERSITY OF TSUKUBA (Japon)
Inventeur(s)
Higashi Taishi
Motoyama Keiichi
Onodera Risako
Matsumoto Yoshitaka
Abrégé
The purpose of the present invention is to provide a novel compound which can serve as a component of a boron pharmaceutical agent. The present application provides a boron-containing modified polyrotaxane comprising a plurality of cyclodextrin molecules, a single straight-chain molecule passing through the openings in the plurality of cyclodextrin molecules in a skewer-like manner, and a blocking group which is provided at both ends of the single straight-chain molecule and prevents the cyclodextrin molecules and the straight-chain molecule from separating, wherein at least some of the cyclodextrin molecules bind, via a linker, to boronic acid or a monovalent group derived therefrom.
This image processing device emits light from a light source onto an examined eye through an optical system of a first numerical aperture, and acquires information indicating interference light obtained by detecting interference light between signal light, in which light returning from the examined eye owing to the light emitted thereon is transmitted through an optical system of a second numerical aperture, and reference light, which is a division of light from the light source (S200). A first process (S202) is performed for projecting information indicating the interference light to a four-dimensional frequency aperture that is on a four-dimensional space of the light source frequency and the frequency of light from the examined eye owing to the signal light, and is formed by the optical system of the first numerical aperture and the optical system of the second numerical aperture. A second process (S204) is performed for projecting the projected information to a three-dimensional space.
A61B 3/10 - Appareils pour l'examen optique des yeux; Appareils pour l'examen clinique des yeux du type à mesure objective, c. à d. instruments pour l'examen des yeux indépendamment des perceptions ou des réactions du patient
G01N 21/17 - Systèmes dans lesquels la lumière incidente est modifiée suivant les propriétés du matériau examiné
36.
METHOD FOR TREATING PATIENT HAVING UNDERGONE PRE-TRANSPLANTATION PROCESS INVOLVED IN HEMATOPOIETIC STEM CELL TRANSPLANTATION, AND COMPOSITION FOR USE IN SAID METHOD
The present disclosure provides: a method for treating a patient who has undergone a pre-transplantation process involved in hematopoietic stem cell transplantation; and a composition for use in said method. The composition according to the present disclosure contains bone-marrow common progenitor cells.
A stage of sleep is easily estimated. A sleep estimation device includes a first acquisition unit configured to acquire blood flow data, a generation unit configured to generate a frequency spectrum of the blood flow data by performing frequency analysis processing on the blood flow data, and a first determination unit configured to determine a stage of sleep of a subject based on the frequency spectrum.
Provided is a robustness verification device comprising: a similar image identification means that uses a degree of similarity between feature amounts obtained by a feature amount extractor to identify a similar image having a predetermined order position in the degree of similarity to the input image in a candidate image group; an order position count means that counts the order position of the similar image with respect to the input image in the candidate image group when adversarial perturbation is applied to the image; a order position calculation means that calculates the order position of the similar image with respect to the input image in the candidate image group when the adversarial perturbation is not applied to the image; and an order position verification means that verifies whether the order position of the similar image counted by the order position count means is within a prescribed range containing the order position of the similar image calculated by the order position calculation means.
G06F 21/57 - Certification ou préservation de plates-formes informatiques fiables, p.ex. démarrages ou arrêts sécurisés, suivis de version, contrôles de logiciel système, mises à jour sécurisées ou évaluation de vulnérabilité
39.
LEARNING DEVICE, LEARNING METHOD, AND RECORDING MEDIUM
This learning device comprises a learning means for performing learning of a feature amount extractor f such that the upper limit and the lower limit of a distance, obtained when the feature amount extractor is used, in a feature space between images become close to the distance.
A paramylon-based resin having a weight-average molecular weight of paramylon in a range of 70000 to 140000, and formed by substituting hydrogen atoms of hydroxy groups of a paramylon with a long-chain component being a linear saturated aliphatic acyl group having 14 or more carbon atoms and a short-chain component being an acyl group (acetyl group or/and propionyl group) having 2 or 3 carbon atoms, wherein a degree of substitution with the long-chain component (DSLo) and a degree of substitution with the short-chain component (DSSh) satisfy the following conditional expressions (1) and (2), Izod impact strength is 5.0 kJ/m2 or more, and an MFR (melt flow rate at 210° C. and under a load of 5 kg) is 2 g/10 min or more. To provide a paramylon-based resin excellent in mechanical characteristics and thermoplasticity. 2.2≤DSLo+DSSh≤2.8 (1) 5≤DSSh/DSLo≤25 (2)
C08B 37/00 - Préparation des polysaccharides non prévus dans les groupes ; Leurs dérivés
41.
SCANNING IMAGING DEVICE, INFORMATION PROCESSING DEVICE, METHOD FOR CONTROLLING SCANNING IMAGING DEVICE, METHOD FOR CONTROLLING INFORMATION PROCESSING DEVICE, INFORMATION PROCESSING METHOD, PROGRAM, AND RECORDING MEDIUM
An ophthalmic examination device 1 according to an embodiment is a scanning imaging device for imaging a sample using optical scanning. The ophthalmic examination device 1 acquires a data set by redundantly collecting data on a sample by the optical scanning using an optical scanner 44, an OCT unit 100, and a control section 210. An image data construction section 220 generates an image set on the basis of the acquired data set. An image selection section 225 selects a plurality of images from the generated image set. An image data processing section 231 executes relative positional adjustment of this image set by applying, to this image set, a plurality of registrations respectively based on the selected plurality of images.
A61B 3/10 - Appareils pour l'examen optique des yeux; Appareils pour l'examen clinique des yeux du type à mesure objective, c. à d. instruments pour l'examen des yeux indépendamment des perceptions ou des réactions du patient
G01N 21/17 - Systèmes dans lesquels la lumière incidente est modifiée suivant les propriétés du matériau examiné
42.
INFORMATION PROCESSING DEVICE, METHOD, AND PROGRAM
A first estimation unit (331) estimates command information per first unit of time using a first trained model (321). A second estimation unit (332) estimates, using a second trained model (322), the command information per second unit of time shorter than the first unit of time, from information corresponding to the command information derived by the first trained model (321). An operation control unit (333) operates a control target device (10B) using the command information estimated by the second estimation unit (332).
NATIONAL AGRICULTURE AND FOOD RESEARCH ORGANIZATION (Japon)
JAPAN INTERNATIONAL RESEARCH CENTER FOR AGRICULTURAL SCIENCES (Japon)
UNIVERSITY OF TSUKUBA (Japon)
KAKE EDUCATIONAL INSTITUTION (Japon)
Inventeur(s)
Hara Takashi
Ishiguro Koji
Otsuka Shiori
Satoh Rie
Matsui Katsuhiro
Suzuki Tatsuro
Yasui Yasuo
Osawa Ryo
Kondo Yasuto
Okamoto Kaoru
Teshima Reiko
Maruyama Kyonoshin
Abrégé
The present invention addresses the problem of providing a Fagopyrum plant having reduced allergen reactivity. In the Fagopyrum plant, the Fag e 2 gene is mutated, and the Fag e 2 protein is deleted. If there is a stop codon mutation in the translation region, it is preferable to have a stop codon mutation so as not to generate a mutant protein having a reduced molecular weight.
NIPPON TELEGRAPH AND TELEPHONE CORPORATION (Japon)
UNIVERSITY OF TSUKUBA (Japon)
Inventeur(s)
Nagata, Masaaki
Wei, Yizhen
Utsuro, Takehito
Abrégé
Provided is an estimation device equipped with: an input unit for inputting an expanded word correspondence for original text and translated text, and a translation quality tag for said original text and said translated text; and an editing tag estimation unit for estimating an editing tag on the basis of the expanded word correspondence and the translation quality tag.
The present invention relates to a pharmaceutical composition for blood cell recovery after allogeneic cord blood transplant, the pharmaceutical composition containing romiplostim as an active ingredient. The pharmaceutical composition is characterized by being administered starting the day after the transplant. The present invention also relates to a method for treating an allogeneic cord blood transplant recipient using the pharmaceutical composition.
Provided is a pavement structure which has good workability and durability and can sustainably draw electricity from an environment such as a facility infrastructure. A pavement structure (1) in which a roadbed layer (2) and a road surface layer (3) supported by the roadbed layer (2) are installed, wherein the roadbed layer (2) comprises a layered part (80) formed by stacking unit structures (81) having a void, and a device part (10) shaped like a box. The device part (10) has a tertiary battery part (30) that generates electricity from variations in electrode temperature and/or a thermoelectric conversion cell part (20) that generates electricity from the difference in temperature between electrodes.
22 in the poly(cysteine) being protected by a hydrophobic alkylcarbonyl, hydrophobic alkylthio, or the like. Also disclosed are self-organizing nanoparticles of such a copolymer and the use of said self-organizing nanoparticles. The copolymer or self-organizing nanoparticles have low toxicity and exhibit efficacy in, e.g., the prevention or treatment of cancer, acute liver injury, inflammatory liver disease, septicemia, or ulcerative colitis through oral administration.
C07K 7/08 - Peptides linéaires ne contenant que des liaisons peptidiques normales ayant de 12 à 20 amino-acides
A61K 38/02 - Peptides à nombre indéterminé d'amino-acides; Leurs dérivés
A61K 47/60 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p.ex. les supports ou les additifs inertes; Agents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p.ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique macromoléculaire, p.ex. une molécule oligomérique, polymérique ou dendrimérique obtenu par des réactions autres que celles faisant intervenir uniquement des liaisons non saturées carbone-carbone, p.ex. polyurées ou polyuréthanes le composé organique macromoléculaire étant un oligomère, un polymère ou un dendrimère de polyoxyalkylène, p.ex. PEG, PPG, PEO ou polyglycérol
A61P 1/16 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif des troubles de la vésicule biliaire ou du foie, p.ex. protecteurs hépatiques, cholagogues, cholélitholytiques
The present invention improves the quality of sleep. According to the present invention, a control device comprises a determination unit that determines the sleep stage of a subject on the basis of bioinformation for the subject and a control unit that controls a sleep induction device that comprises a beat generation unit that generates binaural beats. The control unit makes the beat generation unit generate binaural beats that have a frequency of less than 1.0 Hz at least during the sleep stages of the subject.
A61M 21/02 - Autres dispositifs ou méthodes pour amener un changement dans l'état de conscience; Dispositifs pour provoquer ou arrêter le sommeil par des moyens mécaniques, optiques ou acoustiques, p.ex. pour mettre en état d'hypnose pour provoquer le sommeil ou la relaxation, p.ex. par stimulation directe des nerfs, par hypnose ou par analgésie
49.
ELECTRON SPIN RESONANCE DEVICE AND DETERIORATION EVALUATION METHOD
This electron spin resonance device comprises a hollow resonator having a microwave oscillator, a magnet, a modulation coil, and an opening. Microwaves generated by the microwave oscillator resonate in the hollow resonator and are emitted from the opening toward an object being measured that is positioned outside of the opening. The magnet applies a magnetic field to an irradiated surface at which the object being measured is irradiated with the microwaves. The modulation coil modulates either the strength of the magnetic field applied to the irradiated surface at which the object being measured is irradiated with the microwaves, or the frequency of the microwaves.
G01N 24/10 - Recherche ou analyse des matériaux par l'utilisation de la résonance magnétique nucléaire, de la résonance paramagnétique électronique ou d'autres effets de spin en utilisant la résonance paramagnétique électronique
An object is to elucidate the immune response mechanism of IL-17-producing cells which causes a pathological condition such as psoriasis, and to provide an immune response suppressant for suppressing the immune response of IL-17-producing cells, a medicament for treating or preventing a disease or a pathological condition involving the immune response of an IL-17-producing cell, a method for inducing immune response in γδT cells, and a method for evaluating a medicament (candidate substance) and a method for producing IL-17 by use of the method. The present invention provides an immune response suppressant for an IL-17-producing cell, including a substance that inhibits the binding of CD96 to at least one protein selected from CD155 and CD111, a medicament including the immune response suppressant for an IL-17-producing cell, a method having a step (A) of culturing at least one of a γδT cell and a CD4-positive T cell together with IL-23, an anti-CD3 antibody capable of stimulating a TCR/CD3 complex and an anti-CD96 antibody capable of stimulating CD96, and a method for evaluating a medicament (candidate substance) and a method for producing IL-17, including a method having the step (A).
C07K 16/28 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
G01N 33/50 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique
C12P 21/02 - Préparation de peptides ou de protéines comportant une séquence connue de plusieurs amino-acides, p.ex. glutathion
A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p.ex. agents antirhumatismaux; Médicaments anti-inflammatoires non stéroïdiens [AINS]
Provided is an assistance device which can independently control assistance with knee bending/extending actions and assistance with upper body posture. The assistance device comprises a base, a first link fixed to the base, a second link rotatably linked to the first link, a third link rotatably linked to the second link, and an elastic connection part incorporated between the third link and a prescribed position on the first link or the base.
An image generation device includes a tomographic image acquisition unit configured to acquire an OCTA tomographic image that captures a distribution of a blood flow of an object, a light attenuation acquisition unit configured to acquire a light attenuation of measurement light emitted to the object in a direction in which the tomographic image is layered, and an image generation unit configured to generate a light attenuation-blood flow distribution chart indicating a distribution of the light attenuation based on the acquired OCTA tomographic image and the light attenuation.
A61B 3/12 - Appareils pour l'examen optique des yeux; Appareils pour l'examen clinique des yeux du type à mesure objective, c. à d. instruments pour l'examen des yeux indépendamment des perceptions ou des réactions du patient pour examiner le fond de l'œil, p.ex. ophtalmoscopes
A61B 3/00 - Appareils pour l'examen optique des yeux; Appareils pour l'examen clinique des yeux
A61B 3/10 - Appareils pour l'examen optique des yeux; Appareils pour l'examen clinique des yeux du type à mesure objective, c. à d. instruments pour l'examen des yeux indépendamment des perceptions ou des réactions du patient
This medical imaging equipment has an illumination unit 11 for spot-illuminating the center of a surgical field of a surgery patient, a surgical field camera unit 12 for imaging the center of the range irradiated by the illumination unit 11, a casing 13 for covering the illumination unit 11 and the surgical field camera unit 12, and a pair of display units 14, 14 that can be viewed from both sides of the surgery patient.
A61B 90/30 - Dispositifs pour éclairer une zone chirurgicale, les dispositifs ayant une corrélation avec d’autres dispositifs chirurgicaux ou avec une intervention chirurgicale
H04N 23/53 - Caméras ou modules de caméras comprenant des capteurs d'images électroniques; Leur commande - Détails de structure de viseurs électroniques, p. ex. rotatifs ou détachables
H04N 23/56 - Caméras ou modules de caméras comprenant des capteurs d'images électroniques; Leur commande munis de moyens d'éclairage
54.
COMBINATION THERAPY INVOLVING RADIOTHERAPY AND HYPOXIA-RESPONSIVE PRODRUG OF ANTICANCER DRUG, AND NOVEL HYPOXIA-RESPONSIVE PRODRUG
In the present invention, an anticancer drug/prodrug is used in a combination therapy with radiotherapy. In the chemical formula representing the same, the moiety in which R1 and R2 are bonded to an N atom results from the removal of an amino group or an imino group from an anticancer drug (selected from the group consisting of, e.g., gemcitabine, niraparib, crizotinib, dabrafenib, vemurafenib, entinostat, cobimetinib, palbociclib, and ribociclib) having the amino group or the imino group. Adverse effects from the effect of treating malignant tumors using radiotherapy are thereby reduced, or the effect of the treatment is enhanced.
A61K 31/437 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p.ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle condensés en ortho ou en péri avec des systèmes hétérocycliques le système hétérocyclique contenant un cycle à cinq chaînons ayant l'azote comme hétéro-atome du cycle, p.ex. indolizine, bêta-carboline
A61K 31/4406 - Pyridines non condensées; Leurs dérivés hydrogénés substituées uniquement en position 3, p.ex. zimeldine
A61K 31/4439 - Pyridines non condensées; Leurs dérivés hydrogénés contenant d'autres systèmes hétérocycliques contenant un cycle à cinq chaînons avec l'azote comme hétéro-atome du cycle, p.ex. oméprazole
A61K 31/4523 - Pipéridines non condensées, p.ex. pipérocaïne contenant d'autres systèmes hétérocycliques
A61K 31/454 - Pipéridines non condensées, p.ex. pipérocaïne contenant d'autres systèmes hétérocycliques contenant un cycle à cinq chaînons avec l'azote comme hétéro-atome du cycle, p.ex. pimozide, dompéridone
A61K 31/4545 - Pipéridines non condensées, p.ex. pipérocaïne contenant d'autres systèmes hétérocycliques contenant un cycle à six chaînons avec l'azote comme hétéro-atome du cycle, p.ex. pipampérone, anabasine
A61K 31/506 - Pyrimidines; Pyrimidines hydrogénées, p.ex. triméthoprime non condensées et contenant d'autres hétérocycles
A61K 31/513 - Pyrimidines; Pyrimidines hydrogénées, p.ex. triméthoprime ayant des groupes oxo liés directement à l'hétérocycle, p.ex. cytosine
A61K 31/519 - Pyrimidines; Pyrimidines hydrogénées, p.ex. triméthoprime condensées en ortho ou en péri avec des hétérocycles
A61K 31/704 - Composés ayant des radicaux saccharide liés à des composés non-saccharide par des liaisons glycosidiques liés à un composé carbocyclique, p.ex. phloridzine liés à un système carbocyclique condensé, p.ex. sennosides, thiocolchicosides, escine, daunorubicine, digitoxine
A61K 31/7068 - Composés ayant des radicaux saccharide et des hétérocycles ayant l'azote comme hétéro-atome d'un cycle, p.ex. nucléosides, nucléotides contenant des cycles à six chaînons avec l'azote comme hétéro-atome d'un cycle contenant des pyrimidines condensées ou non-condensées ayant des groupes oxo liés directement au cycle pyrimidine, p.ex. cytidine, acide cytidylique
A61K 47/54 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p.ex. les supports ou les additifs inertes; Agents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p.ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique
A61P 43/00 - Médicaments pour des utilisations spécifiques, non prévus dans les groupes
C07D 401/12 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
C07D 401/14 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant au moins trois hétérocycles
C07D 417/14 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes de soufre et d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant au moins trois hétérocycles
This SREBP-1 inhibitor has inhibitory activity against SREBP-1 and does not have inhibitory activity against SREBP-2, the SREBP-1 inhibitor containing, as an active ingredient, one or more compounds from among compounds represented by formulas (1) to (23). This pharmaceutical composition for treating hypertriglyceridemia contains the aforementioned SREBP-1 inhibitor and a pharmacologically acceptable carrier.
A61K 31/341 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p.ex. fungichromine ayant des cycles à cinq chaînons avec un oxygène comme seul hétéro-atome d'un cycle, p.ex. isosorbide non condensés avec un autre cycle, p.ex. ranitidine, furosémide, bufétolol, muscarine
A61K 31/381 - Composés hétérocycliques ayant le soufre comme hétéro-atome d'un cycle ayant des cycles à cinq chaînons
A61K 31/4025 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p.ex. guanéthidine ou rifamycines ayant des cycles à cinq chaînons avec un azote comme seul hétéro-atome d'un cycle, p.ex. sulpiride, succinimide, tolmétine, buflomédil non condensés et contenant d'autres hétérocycles, p.ex. cromakalim
A61K 31/403 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p.ex. guanéthidine ou rifamycines ayant des cycles à cinq chaînons avec un azote comme seul hétéro-atome d'un cycle, p.ex. sulpiride, succinimide, tolmétine, buflomédil condensés avec des carbocycles, p.ex. carbazole
A61K 31/427 - Thiazoles non condensés et contenant d'autres hétérocycles
A61K 31/4365 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p.ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle condensés en ortho ou en péri avec des systèmes hétérocycliques le système hétérocyclique ayant le soufre comme hétéro-atome du cycle, p.ex. ticlopidine
A61K 31/437 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p.ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle condensés en ortho ou en péri avec des systèmes hétérocycliques le système hétérocyclique contenant un cycle à cinq chaînons ayant l'azote comme hétéro-atome du cycle, p.ex. indolizine, bêta-carboline
A61K 31/4535 - Pipéridines non condensées, p.ex. pipérocaïne contenant d'autres systèmes hétérocycliques contenant un hétérocycle avec le soufre comme hétéro-atome du cycle, p.ex. pizotifène
A61K 31/4709 - Quinoléines non condensées contenant d'autres hétérocycles
A61K 31/4745 - Quinoléines; Isoquinoléines condensées en ortho ou en péri avec des systèmes hétérocycliques condensées avec des systèmes cycliques ayant l'azote comme hétéro-atome d'un cycle, p.ex. phénanthrolines
A61K 31/506 - Pyrimidines; Pyrimidines hydrogénées, p.ex. triméthoprime non condensées et contenant d'autres hétérocycles
A61K 31/513 - Pyrimidines; Pyrimidines hydrogénées, p.ex. triméthoprime ayant des groupes oxo liés directement à l'hétérocycle, p.ex. cytosine
A61K 31/519 - Pyrimidines; Pyrimidines hydrogénées, p.ex. triméthoprime condensées en ortho ou en péri avec des hétérocycles
C07D 209/88 - Carbazoles; Carbazoles hydrogénés avec des hétéro-atomes ou des atomes de carbone comportant trois liaisons à des hétéro-atomes avec au plus une liaison à un halogène, p.ex. radicaux ester ou nitrile, liés directement aux atomes de carbone du système cyclique
C07D 231/44 - Atomes d'oxygène et d'azote ou atomes de soufre et d'azote
C07D 333/38 - Atomes de carbone comportant trois liaisons à des hétéro-atomes avec au plus une liaison à un halogène, p.ex. radicaux ester ou nitrile
C07D 401/04 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant deux hétérocycles liés par une liaison directe de chaînon cyclique à chaînon cyclique
C07D 403/06 - Composés hétérocycliques contenant plusieurs hétérocycles, comportant des atomes d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant deux hétérocycles liés par une chaîne carbonée ne contenant que des atomes de carbone aliphatiques
C07D 405/12 - Composés hétérocycliques contenant à la fois un ou plusieurs hétérocycles comportant des atomes d'oxygène comme uniques hétéro-atomes du cycle et un ou plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
C07D 409/12 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes de soufre comme uniques hétéro-atomes du cycle contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
C07D 413/14 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes d'azote et d'oxygène comme uniques hétéro-atomes du cycle contenant au moins trois hétérocycles
C07D 417/10 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes de soufre et d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant deux hétérocycles liés par une chaîne carbonée contenant des cycles aromatiques
C07D 491/22 - Composés hétérocycliques contenant dans le système cyclique condensé, à la fois un ou plusieurs cycles comportant des atomes d'oxygène comme uniques hétéro-atomes du cycle, et un ou plusieurs cycles comportant des atomes d'azote comme uniques hétéro- dans lesquels le système condensé contient au moins quatre hétérocycles
One aspect of the present invention is a humanized anti-DNAM-1 antibody or an antigen-binding fragment thereof, having: a heavy chain variable region comprising an amino acid sequence represented by SEQ ID NO: 1, serving as HCDR1, an amino acid sequence represented by SEQ ID NO: 2, serving as HCDR2, and an amino acid sequence represented by SEQ ID NO: 3, serving as HCDR3; and a light chain variable region comprising an amino acid sequence represented by SEQ ID NO: 4, serving as LCDR1, an amino acid sequence represented by SEQ ID NO: 5, serving as LCDR2, and an amino acid sequence represented by SEQ ID NO: 6, serving as LCDR3.
A61P 37/06 - Immunosuppresseurs, p.ex. médicaments pour le traitement du rejet de greffe
C07K 16/28 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
C12N 1/15 - Champignons; Leurs milieux de culture modifiés par l'introduction de matériel génétique étranger
C12N 1/19 - Levures; Leurs milieux de culture modifiés par l'introduction de matériel génétique étranger
C12N 1/21 - Bactéries; Leurs milieux de culture modifiés par l'introduction de matériel génétique étranger
C12N 5/10 - Cellules modifiées par l'introduction de matériel génétique étranger, p.ex. cellules transformées par des virus
C12N 15/63 - Introduction de matériel génétique étranger utilisant des vecteurs; Vecteurs; Utilisation d'hôtes pour ceux-ci; Régulation de l'expression
57.
DISEASE-CONDITION ASSESSMENT DEVICE, DISEASE-CONDITION ASSESSMENT METHOD, PROGRAM FOR DISEASE-CONDITION ASSESSMENT DEVICE, AND DISEASE-CONDITION ASSESSMENT SYSTEM
NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY (Japon)
UNIVERSITY OF TSUKUBA (Japon)
YAZAKI CORPORATION (Japon)
SUBARU CORPORATION (Japon)
MITSUBISHI ELECTRIC CORPORATION (Japon)
Inventeur(s)
Komine, Hidehiko
Kitazaki, Satoshi
Akakatsu, Motoyuki
Ishii, Kei
Tsurushima, Hideo
Shino, Motoki
Abrégé
Provided are a disease-condition assessment device for being capable of assessing an epileptic condition of a subject, a disease-condition assessment method, a program for disease-condition assessment device, and a disease-condition assessment system. The gaze data indicating a subject's gazing point measured when the subject is driving a vehicle is acquired, the driving-characteristic data indicating driving characteristics of the subject for the vehicle is acquired), and the epileptic condition of the subject is assessed depending on the relationship between the gaze data and the driving-characteristic data.
B60W 40/08 - Calcul ou estimation des paramètres de fonctionnement pour les systèmes d'aide à la conduite de véhicules routiers qui ne sont pas liés à la commande d'un sous-ensemble particulier liés aux conducteurs ou aux passagers
A61B 5/00 - Mesure servant à établir un diagnostic ; Identification des individus
G06V 20/59 - Contexte ou environnement de l’image à l’intérieur d’un véhicule, p.ex. concernant l’occupation des sièges, l’état du conducteur ou les conditions de l’éclairage intérieur
58.
PARAMYLON-BASED RESIN, MOLDING MATERIAL, MOLDED BODY, AND PRODUCTION METHOD FOR PARAMYLON-BASED RESIN
A paramylon-based resin excellent in mechanical characteristics and thermoplasticity is provided. The present embodiment provides a paramylon-based resin in which hydrogen atoms of hydroxy groups of paramylon are substituted by linear saturated aliphatic acyl group having 14 or more carbon atoms as a long chain component and/or acyl group having 2 or 3 carbon atoms (acetyl group or/and propionyl group) as a short chain component, wherein the paramylon has a weight average molecular weight in the range of more than 140000 to 220000 and a molecular weight distribution (weight average molecular weight/number average molecular weight) of 6.5 or less, a protein content of the paramylon is 0.22% by mass to 5.0% by mass, and a degree of substitution (DSLo) by the long chain component and a degree of substitution (DSSh) by the short chain component satisfy the following expressions (S1), (L1) and (T1); 1.7≤DSSh≤2.8 (S1), 0≤DSLo≤0.4 (L1), 2.1≤DSLo+DSSh≤2.8 (T1).
KANAGAWA INSTITUTE OF INDUSTRIAL SCIENCE AND TECHNOLOGY (Japon)
UNIVERSITY OF TSUKUBA (Japon)
METAGEN, INC. (Japon)
Inventeur(s)
Fukuda Shinji
Nakato Gaku
Obana Nozomu
Furukawa Risako
Abrégé
The present invention addresses the problem of revealing a symptom onset mechanism of allergies in which bacteria belonging to the family Lachnospiraceae including Ruminococcus gnavus (R. gnavus) which is an enteric bacterium is involved, and developing a means for preventing or treating allergies by intervening in the mechanism. As a result of conducting thorough investigation, the present inventors have found that Ibp protein from bacteria belonging to the family Lachnospiraceae is involved in the onset of allergies, and have shown that said problem can be solved. Specifically, it is possible to prevent allergic reactions occurring in a body by administering, to the body, or inducing production of, within the body, a substance that binds to Ibp protein from bacteria belonging to the family Lachnospiraceae.
C12Q 1/02 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismes; Compositions à cet effet; Procédés pour préparer ces compositions faisant intervenir des micro-organismes viables
G01N 33/68 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir des protéines, peptides ou amino-acides
C07K 14/195 - Peptides ayant plus de 20 amino-acides; Gastrines; Somatostatines; Mélanotropines; Leurs dérivés provenant de bactéries
60.
MEASUREMENT SIGNAL PROCESSING DEVICE, MEASUREMENT SIGNAL PROCESSING METHOD, AND PROGRAM
A model learning unit determines a model parameter for calculating an estimated value for each of a plurality of training sets, each including a measurement signal and at least one type of predetermined characteristic value indicating characteristics of the measurement signal as a target value, to minimize a difference between the estimated value calculated for the measurement signal using a predetermined mathematical model and the target value is minimized, determines characteristic value sets, each being a set of a plurality of types of characteristic values indicating characteristics of the measurement signal including the target value, with which, for each target value, the target value is common to a plurality of characteristic value sets, and generates, for each of the characteristic value sets, each of the plurality of training sets including the target value and a measurement signal having characteristics indicated by the plurality of types of characteristic values.
Provided is a measuring device comprising on a substrate, for example: N (N is an integer of 1 or more) first terminals respectively electrically connected to a maximum of M (M is an integer of 1 or more) anodes; and M second terminals respectively electrically connected to a maximum of N cathodes, wherein each of the anodes is electrically connected to one of the first terminals, each of the cathodes is electrically connected to one of the second terminals, M and/or N is 2 or more, when M is 2 or more, the anode and the corresponding cathode electrically connected to the same first terminal are electrically connected to different second terminals, and when N is 2 or more, the cathode and the corresponding anode electrically connected to the same second terminal are electrically connected to different first terminals.
G01N 27/27 - Association de plusieurs systèmes ou cellules de mesure, chacun mesurant un paramètre différent, dans laquelle les résultats des mesures peuvent être, soit utilisès indépendamment, les systèmes ou les cellules étant physiquement associés, soit combin
G01N 27/404 - Cellules avec l'anode, la cathode et l'électrolyte de la cellule du même côté d'une membrane perméable qui les sépare du fluide de l'échantillon
NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY (Japon)
UNIVERSITY OF TSUKUBA (Japon)
TAIYO SERVICE INC. (Japon)
Inventeur(s)
Iwata, Yasushi
Matsui, Hirofumi
Suzuki, Iwane
Suzuki, Yuji
Tomita, Kanako
Yang, Tianjing
Ikeda, Takafumi
Kurokawa, Hiromi
Abrégé
Provided is an anticancer agent containing nitrogen 15 and also containing a substance that is accumulated specifically in cancer cells. Also provided is a method for killing cancer cells in vitro, said method comprising accumulating nitrogen 15 in cancer cells in vitro and irradiating the cancer cells with proton beams in vitro. Also provided is a cancer therapy method comprising accumulating nitrogen 15 in cancer cells of a human or a non-human animal and irradiating the human or non-human animal with proton beams.
A61K 41/00 - Préparations médicinales obtenues par traitement de substances par énergie ondulatoire ou par rayonnement corpusculaire
A61K 31/197 - Acides carboxyliques, p.ex. acide valproïque ayant un groupe amino les groupes amino et carboxyle étant liés à la même chaîne carbone acyclique, p.ex. acide gamma-aminobutyrique (GABA), bêta-alanine, acide epsilon-aminocaproïque, acide pantothénique
A61K 31/513 - Pyrimidines; Pyrimidines hydrogénées, p.ex. triméthoprime ayant des groupes oxo liés directement à l'hétérocycle, p.ex. cytosine
A61K 45/00 - Préparations médicinales contenant des ingrédients actifs non prévus dans les groupes
A61K 47/68 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p.ex. les supports ou les additifs inertes; Agents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p.ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un anticorps, une immunoglobuline ou son fragment, p.ex. un fragment Fc
A61N 5/10 - Radiothérapie; Traitement aux rayons gamma; Traitement par irradiation de particules
This intraocular illumination device comprises: a fiber for guiding light from a light source; and a holder which is disposed between an objective lens of a microscope and an eye during surgery or inspection of the eye and which supports the leading end of the fiber. Provided to the leading end of the fiber is a reflective part on which the light guided through the fiber is reflected toward the interior of the eye.
By using this therapeutic device (1) which is characterized in that a shape of a target (30) is estimated using an identifier (61) trained on the basis of a first image (23) in which subject in vivo information is captured, a second image (30) showing the target (63) in vivo, and a third image (20) capturing the same subject using a different device from the first image (23), it is possible to accurately estimate the shape of a target treatment area when carrying out training on the shape of a target treatment area using a DRR image processed from a CT image.
This information processing device comprises a reception unit for receiving a plurality of OCT images captured under different imaging conditions and represented by complex signals, an image processing unit for performing digital refocusing by complex signal processing or digital aberration correction by complex signal processing for each of the plurality of OCT images received by the reception unit, and a synthesis unit for synthesizing the plurality of OCT images subjected to digital refocusing by complex signal processing or digital aberration correction by complex signal processing by the image processing unit.
The invention provides an HIF-1 activator for treatment, prevention, alleviation, improvement or recovery from diseases or symptoms associated with reduced HIF-1 activity, as well as a pharmaceutical composition, cosmetic and food composition comprising the activator. Provided is an HIF-1 activator comprising olive leaf extract. Also provided is an HIF-1 activator which is for maintaining the undifferentiated state of stem cells via HIF-1 activation and/or improving dysdifferentiation of stem cells.
A61K 36/63 - Oleaceae (famille de l'olive), p.ex. jasmin, lilas ou frêne
A61K 31/7048 - Composés ayant des radicaux saccharide et des hétérocycles ayant l'oxygène comme hétéro-atome d'un cycle, p.ex. leucoglucosane, hespéridine, érythromycine, nystatine
A mobility support device capable of stably climbing a step without impairing mobility on flat ground is provided. The mobility support device includes a front wheel, a rear wheel, a drive wheel disposed between the front wheel and the rear wheel, a first link coupled to the front wheel, a second link connecting the drive wheel and the rear wheel, a rotation joint coupling the first link and the second link at a first position, and a first elastic member coupling the first link and the second link at a second position different from the first position.
A61G 5/06 - Fauteuils ou moyens de transport personnels spécialement adaptés pour des personnes handicapées, p.ex. fauteuils roulants avec dispositions pour franchir les obstacles, p.ex. pour monter les escaliers
A61G 5/10 - Fauteuils ou moyens de transport personnels spécialement adaptés pour des personnes handicapées, p.ex. fauteuils roulants - Parties constitutives, détails ou accessoires
68.
TRAINED MODEL GENERATION PROGRAM, IMAGE GENERATION PROGRAM, TRAINED MODEL GENERATION DEVICE, IMAGE GENERATION DEVICE, TRAINED MODEL GENERATION METHOD, AND IMAGE GENERATION METHOD
A trained model generation program causes a computer to implement a learning execution function of inputting first input image data representing a first input image generated by a first reconstruction method using compressed sensing and second input image data representing a second input image generated by a second reconstruction method different from the first reconstruction method to a machine learning device to execute machine learning, the second reconstruction method being an analytical reconstruction method, and causing the machine learning device to generate a trained model, and a trained model acquisition function of acquiring trained model data indicating the trained model. Then, input image data representing an input image is input to the trained model to generate a reconstructed image with improved image quality.
G06V 10/82 - Dispositions pour la reconnaissance ou la compréhension d’images ou de vidéos utilisant la reconnaissance de formes ou l’apprentissage automatique utilisant les réseaux neuronaux
The present invention addresses the problem of increasing backup force that is exerted when a medical device is introduced into a bifurcation while reducing the possibility of vascular damage that may occur when the medical device approaches the bifurcation. An introduction aid (11, 31, 51) for use when a medical device (catheter 22) is introduced into a bifurcation (B) of a blood vessel (aorta A) comprises: a tube (outer sheath 111, 311, 511) having a first passage (P1) that extends from a proximal end (11P, 31P) to a distal end (11E, 31E) having a tapered shape and a second passage (P2) that extends from the proximal end (11P, 31P) to a side hole (Hs); and a flexible inner tube (inner sheath 115, 515) that is introduced into the second passage from the proximal end, with a tip end thereof reaching the side hole. A portion of the inner tube near the tip end is continuously and smoothly bent so that no step is created when the inner tube is not introduced into the second passage.
NATIONAL UNIVERSITY CORPORATION TOKAI NATIONAL HIGHER EDUCATION AND RESEARCH SYSTEM (Japon)
UNIVERSITY OF TSUKUBA (Japon)
Inventeur(s)
Mori, Kensaku
Oda, Masahiro
Oshika, Tetsuro
Ueno, Yuta
Yamaguchi, Takefumi
Fukuoka, Hideki
Abrégé
A diagnostic imaging support device includes: a learning unit that calculates a feature quantity about each of infectiousness condition and non-infectiousness condition for determining a condition in a determination image of an anterior eye through machine learning on the basis of a learning image of an anterior eye and information about a condition in the learning image.
H04N 7/173 - Systèmes à secret analogiques; Systèmes à abonnement analogiques à deux voies, p.ex. l'abonné envoyant un signal de sélection du programme
H04N 5/85 - Enregistrement du signal de télévision utilisant l'enregistrement optique sur des disques ou sur des tambours
71.
STRUCTURE ESTIMATION PROGRAM, STRUCTURE ESTIMATION DEVICE, AND STRUCTURE ESTIMATION METHOD
This structure estimation program causes a computer to perform a proximity data acquisition function to acquire proximity data, which is data relating to whether an element that is included in a object having a one-dimensional sequence and that makes up said one-dimensional sequence is at a distance less than or equal to a prescribed distance from another element of the one-dimensional sequence, and a reconstruction function to reconstruct the proximity data and generate rough structure data indicating the structure of the object, use a nearby point in the structure of the object as indicated by the rough structure data to generate first structure data indicating the structure of the object at a higher spatial resolution than the rough structure data, and use a nearby point in the structure of the object as indicated by the first structure data to generate second structure data indicating the structure of the object at a higher spatial resolution than the first structure data.
G16B 15/00 - TIC spécialement adaptées à l’analyse de structures moléculaires bidimensionnelles ou tridimensionnelles, p.ex. relations structurelles ou fonctionnelles ou alignement de structures
72.
SEMICONDUCTOR APPARATUS AND METHOD FOR MANUFACTURING SEMICONDUCTOR APPARATUS
This semiconductor apparatus has a substrate film and a semiconductor film formed on the substrate film, wherein the substrate film comprises a polyimide obtained by condensation polymerization of an aromatic diamine and an aromatic tetracarboxylic acid anhydride and has a tensile elasticity in the longitudinal direction of 7 GPa or more, and the semiconductor film is polycrystalline and comprises crystal particles having an average particle size of 1 μm or more.
H01L 21/20 - Dépôt de matériaux semi-conducteurs sur un substrat, p.ex. croissance épitaxiale
C08G 73/10 - Polyimides; Polyester-imides; Polyamide-imides; Polyamide-acides ou précurseurs similaires de polyimides
H01L 21/336 - Transistors à effet de champ à grille isolée
H01L 27/12 - Dispositifs consistant en une pluralité de composants semi-conducteurs ou d'autres composants à l'état solide formés dans ou sur un substrat commun comprenant des éléments de circuit passif intégrés avec au moins une barrière de potentiel ou une barrière de surface le substrat étant autre qu'un corps semi-conducteur, p.ex. un corps isolant
This method for producing a carbon nanotube strand wire includes: a first step in which a carbon-containing gas is supplied from one first end section of a tubular carbon nanotube synthesis furnace and a carbon nanotube is grown from each of a plurality of catalyst particles in a suspended state inside the carbon nanotube synthesis furnace to thus synthesize a plurality of carbon nanotubes; a second step in which the plurality of carbon nanotubes are assembled by aligning along the length direction of the carbon nanotubes in a first flow channel provided inside the carbon nanotube synthesis furnace to thus form a carbon nanotube strand wire; and a third step in which the carbon nanotube strand wire is recovered from a second end section, which is opposite to the first end section, of the carbon nanotube synthesis furnace, using a recovery gas flow that flows in a direction of separation from the carbon nanotube synthesis furnace.
C01B 32/164 - Préparation faisant intervenir des procédés continus
D01F 9/10 - Filaments, ou similaires, faits par l’homme, formés d’autres substances; Leur fabrication; Appareils spécialement adaptés à la fabrication de filaments de carbone de matière inorganique par décomposition de substances organiques
74.
METHOD FOR PRODUCING CARBON NANOTUBE STRAND WIRE AND CARBON NANOTUBE STRAND WIRE PRODUCTION DEVICE
As a method for producing a carbon nanotube strand wire capable of efficiently producing a carbon nanotube strand wire in a tubular carbon nanotube synthesis furnace, a gas flow for adhesion suppression is generated from a gas for adhesion suppression release port located between the second end of the carbon nanotube synthesis furnace (side on which carbon nanotube strand wire is recovered) and the end in the heating device on the second end side in a direction from the second end toward the first end (side on which carbon-containing gas is supplied) between the inner wall of the carbon nanotube synthesis furnace and the outer wall of a first flow path for orienting carbon nanotubes to form a carbon nanotube strand wire to suppress the adhesion of a plurality of carbon nanotubes to the inner walls of the carbon nanotube synthesis furnace.
There is provided a mutant KLF protein that can induce reprogramming of a somatic cell at a higher efficiency than a KLF protein having a natural amino acid sequence. There is also provided a method for efficiently producing an iPS cell by using the mutant KLF protein. There is provided a mutant KLF protein having an amino acid substitution, or a peptide fragment thereof containing the amino acid substitution.
C12N 15/85 - Vecteurs ou systèmes d'expression spécialement adaptés aux hôtes eucaryotes pour cellules animales
C07K 14/47 - Peptides ayant plus de 20 amino-acides; Gastrines; Somatostatines; Mélanotropines; Leurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
The present invention provides a novel copolymer which is able to be used as a marking agent for a specific part of a biological tissue, and which is also able to be used as a photosensitizer that is topically administered in PDT therapy. A copolymer which comprises a repeating unit represented by formula (I) and a repeating unit represented by formula (II).
C08F 220/60 - Amides contenant de l'azote en plus de l'azote de la fonction carbonamide
C07D 487/22 - Composés hétérocycliques contenant des atomes d'azote comme uniques hétéro-atomes dans le système condensé, non prévus par les groupes dans lesquels le système condensé contient au moins quatre hétérocycles
[Problem] To provide an underwater positioning system and method capable of accurate underwater positioning. [Solution] The underwater positioning system 1 in which at least one among one or more transmitters 2 and one or more receivers 3 is provided at known coordinates, and which positions an unknown point of unknown coordinates in which another transmitter 2 or receiver 3 is provided, comprises: a time window DB 4 that, when unknown points are set within a plurality of regions R set by dividing an underwater positioning range, stores in advance for each region R, a time window for sound waves emitted from the transmitter 2 to reach the receiver 3; and a coordinate estimation/specification unit 6 that calculates, for each region R, a time-windowed impulse response, which is an inner product of the time window and an impulse response of a sound wave propagation path from the transmitter 2 to the receiver 3, and estimates that the unknown point is located in the region R where the energy of the time-windowed impulse response is at maximum.
nn (wherein n ≥ 4, provided that n is an integer); and an electron donor. At least some of the electron donor is supported by the borohydride-containing sheet; electrons of the electron donor are supplied to the borohydride-containing sheet by external stimuli; and hydrogen is generated from the borohydride-containing sheet into which the electrons have been injected.
C01B 6/00 - Hydrures de métaux; Monoborane ou diborane; Leurs complexes d'addition
C01B 3/04 - Production d'hydrogène ou de mélanges gazeux contenant de l'hydrogène par décomposition de composés inorganiques, p.ex. de l'ammoniac
H01M 8/065 - Combinaison d’éléments à combustible avec des moyens de production de réactifs ou pour le traitement de résidus avec des moyens de production des réactifs gazeux par déshydruration de substances métalliques
79.
COMPOSITION FOR PREVENTING OR TREATING TISSUE AGING
NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY (Japon)
UNIVERSITY OF TSUKUBA (Japon)
Inventeur(s)
Namihira, Masakazu
Hayashi, Yoshiki
Abrégé
Provided is a composition for preventing or treating tissue aging which contains an S-adenosylmethionine synthase inhibitor. Also provided is a method for screening an anti-aging substance, the method comprising (1) a step for culturing fibroblasts in the presence of a candidate compound, (2) a step for evaluating the propagating capability of the fibroblasts, and (3) a step for quantitatively determining the S-adenosylmethionine in the fibroblasts.
A61K 45/00 - Préparations médicinales contenant des ingrédients actifs non prévus dans les groupes
A61K 31/519 - Pyrimidines; Pyrimidines hydrogénées, p.ex. triméthoprime condensées en ortho ou en péri avec des hétérocycles
A61K 31/7105 - Acides ribonucléiques naturels, c. à d. contenant uniquement des riboses liés à l'adénine, la guanine, la cytosine ou l'uracile et ayant des liaisons 3'-5' phosphodiester
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiques; Thérapie génique
A61P 15/00 - Médicaments pour le traitement des troubles génitaux ou sexuels; Contraceptifs
A61P 17/00 - Médicaments pour le traitement des troubles dermatologiques
A61P 25/00 - Médicaments pour le traitement des troubles du système nerveux
A61P 43/00 - Médicaments pour des utilisations spécifiques, non prévus dans les groupes
C12N 5/071 - Cellules ou tissus de vertébrés, p.ex. cellules humaines ou tissus humains
C12N 15/113 - Acides nucléiques non codants modulant l'expression des gènes, p.ex. oligonucléotides anti-sens
C12N 15/115 - Aptamères, c. à d. acides nucléiques liant spécifiquement une molécule cible avec une haute affinité sans s'y hybrider
C12N 15/85 - Vecteurs ou systèmes d'expression spécialement adaptés aux hôtes eucaryotes pour cellules animales
C12Q 1/02 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismes; Compositions à cet effet; Procédés pour préparer ces compositions faisant intervenir des micro-organismes viables
C12Q 1/25 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismes; Compositions à cet effet; Procédés pour préparer ces compositions faisant intervenir des enzymes qui ne peuvent pas être classées dans les groupes
G01N 33/50 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique
80.
FLYING OBJECT CONTROL SYSTEM, FLYING OBJECT CONTROL METHOD, AND PROGRAM
Provided is a flying object control system comprising an area-forming part that forms a prescribed area relative to a grip, a detection unit that detects a displacement of the prescribed area formed by the area-forming part, and a control unit that controls the flight of a flying object on the basis of the displacement of the prescribed area detected by the detection unit.
B64C 13/20 - Dispositifs amorçant la mise en œuvre actionnés automatiquement, p.ex. répondant aux détecteurs de rafales utilisant des émissions de signaux
B64C 39/02 - Aéronefs non prévus ailleurs caractérisés par un emploi spécial
G05D 1/00 - Commande de la position, du cap, de l'altitude ou de l'attitude des véhicules terrestres, aquatiques, aériens ou spatiaux, p.ex. pilote automatique
G05D 1/10 - Commande de la position ou du cap dans les trois dimensions simultanément
81.
HYDROGEN STORAGE AND RELEASE MATERIAL AND METHOD OF PRODUCING SAME
The present invention provides a hydrogen storage and release material including a two-dimensional hydrogen boride-containing sheet including a two-dimensional network containing n(HxBy) (n≥4, 0.001≤x/y≤0.999) having a molar ratio of boron to hydrogen from 1:0.999 to 1:0.001, the molar ratio being determined by thermal desorption spectroscopy, and mass measurement before and after a temperature rise, wherein the hydrogen storage and release material has: peaks derived from B1s of boron at 187.5±1.0 eV and 191.2±1.0 eV to 193±1.0 eV in X-ray photoelectron spectroscopy, and a peak derived from a B—H stretching vibration at from 2400 cm−1 to 2600 cm−1 and also a peak derived from a B—H—B stretching vibration at from 1200 cm−1 to 1800 cm−1 in infrared spectroscopy.
C01B 3/00 - Hydrogène; Mélanges gazeux contenant de l'hydrogène; Séparation de l'hydrogène à partir de mélanges en contenant; Purification de l'hydrogène
C01B 6/10 - Monoborane; Diborane; Leurs complexes d'addition
[Problem] To provide a valproic acid derivative for improving the disadvantages or faults associated with using valproic acid itself as medicine. [Solution] Provided is a polymeric compound of valproic acid that is a block copolymer containing a poly(ethylene glycol) segment and a poly(valproic acid vinyl) segment.
C08F 293/00 - Composés macromoléculaires obtenus par polymérisation sur une macromolécule contenant des groupes capables d'amorcer la formation de nouvelles chaînes polymères rattachées exclusivement à une ou aux deux extrémités de la macromolécule de départ
A61K 9/14 - Préparations médicinales caractérisées par un aspect particulier à l'état particulaire, p.ex. poudres
A61K 47/58 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p.ex. les supports ou les additifs inertes; Agents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p.ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique macromoléculaire, p.ex. une molécule oligomérique, polymérique ou dendrimérique obtenu par des réactions faisant intervenir uniquement des liaisons non saturées carbone-carbone, p.ex. poly[méth]acrylate, polyacrylamide, polystyrène, polyvinylpyrrolidone, alcool polyvinylique ou résine d’acide sulfonique de polystyrène
A61K 47/60 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p.ex. les supports ou les additifs inertes; Agents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p.ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique macromoléculaire, p.ex. une molécule oligomérique, polymérique ou dendrimérique obtenu par des réactions autres que celles faisant intervenir uniquement des liaisons non saturées carbone-carbone, p.ex. polyurées ou polyuréthanes le composé organique macromoléculaire étant un oligomère, un polymère ou un dendrimère de polyoxyalkylène, p.ex. PEG, PPG, PEO ou polyglycérol
The purpose of the present invention is to provide an excellent method for storing and transporting hydrogen. The structural body according to the present invention includes boron, hydrogen and oxygen, and has a B-H-B bond, a B-H bond, and a B-OH bond. When an FT-IR spectrum is measured, the structural body satisfies formula (1) 0.80≤a/c≤0.96 and formula (2) 0.95≤b/c≤1.12 (in the formulae, a represents the transmission rate at 1400 cm-1in the FT-IR spectrum, b represents the transmission rate at 2500 cm-1in the FT-IR spectrum, and c represents the transmission rate at 3200 cm-1 in the FT-IR spectrum).
C01B 3/00 - Hydrogène; Mélanges gazeux contenant de l'hydrogène; Séparation de l'hydrogène à partir de mélanges en contenant; Purification de l'hydrogène
C01B 3/04 - Production d'hydrogène ou de mélanges gazeux contenant de l'hydrogène par décomposition de composés inorganiques, p.ex. de l'ammoniac
C01B 6/04 - Hydrures des métaux alcalins, des métaux alcalino-terreux, du béryllium ou du magnésium; Leurs complexes d'addition
C01B 6/10 - Monoborane; Diborane; Leurs complexes d'addition
[Problem] To provide a valproic acid derivative for improving the disadvantages or faults associated with using valproic acid itself as medicine. [Solution] Provided is a polymeric compound of valproic acid that is a block copolymer containing a poly(ethylene glycol) segment and a poly(valproic acid vinyl) segment.
C08F 293/00 - Composés macromoléculaires obtenus par polymérisation sur une macromolécule contenant des groupes capables d'amorcer la formation de nouvelles chaînes polymères rattachées exclusivement à une ou aux deux extrémités de la macromolécule de départ
A61K 47/58 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p.ex. les supports ou les additifs inertes; Agents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p.ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique macromoléculaire, p.ex. une molécule oligomérique, polymérique ou dendrimérique obtenu par des réactions faisant intervenir uniquement des liaisons non saturées carbone-carbone, p.ex. poly[méth]acrylate, polyacrylamide, polystyrène, polyvinylpyrrolidone, alcool polyvinylique ou résine d’acide sulfonique de polystyrène
A61K 47/60 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p.ex. les supports ou les additifs inertes; Agents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p.ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique macromoléculaire, p.ex. une molécule oligomérique, polymérique ou dendrimérique obtenu par des réactions autres que celles faisant intervenir uniquement des liaisons non saturées carbone-carbone, p.ex. polyurées ou polyuréthanes le composé organique macromoléculaire étant un oligomère, un polymère ou un dendrimère de polyoxyalkylène, p.ex. PEG, PPG, PEO ou polyglycérol
A61K 9/14 - Préparations médicinales caractérisées par un aspect particulier à l'état particulaire, p.ex. poudres
A phase gradient calculation unit calculates a phase gradient on a plane intersecting an irradiation direction of light corresponding to an optical coherence tomography signal indicating a state of a sample for each of sample points arranged on the plane. A bulk phase error calculation unit integrates, for each of plurality of paths from an origin that is a sample point where a bulk phase error is determined to a destination that is a sample point where the bulk phase error is not determined, the phase gradient for each of the sample points along each of the plurality of corresponding paths to calculate a path specific phase error at the destination, and combines the path specific phase errors among the plurality of corresponding paths to determine the bulk phase error at the destination.
Provided is an evaluation method for a biological tissue that enables dynamics of the biological tissue to be quantitatively evaluated. In the evaluation method of the present embodiment, an optical coherence tomography (OCT) signal indicating a state of a biological tissue provided as a sample is acquired, a signal value based on the OCT signal is acquired at an observation point in the sample, and a temporal variation characteristic value indicating a temporal variation characteristic of the signal value within a predetermined period is calculated. The present embodiment can also be implemented with an evaluation device or even with a program.
This cold sensation presentation device comprises: a cold stimulation unit that applies a cold stimulus to a skin in a noncontact manner; a warm stimulation unit that applies a warm stimulus to the skin in a noncontact manner; and a control unit that presents a cold sensation by making different from each other a change over time in intensity of the cold stimulus in a cold stimulation state in which the intensity of the warm stimulus is relatively low and a change over time in intensity of the warm stimulus in a warm stimulation state in which the intensity of the warm stimulus is relatively high and by repeating the cold stimulation state and the warm stimulation state in a state in which the intensity of the cold stimulus is maintained constant.
G06F 3/01 - Dispositions d'entrée ou dispositions d'entrée et de sortie combinées pour l'interaction entre l'utilisateur et le calculateur
A61B 10/00 - Autres méthodes ou instruments pour le diagnostic, p.ex. pour le diagnostic de vaccination; Détermination du sexe; Détermination de la période d'ovulation; Instruments pour gratter la gorge
88.
POLY(ETHYLENE GLYCOL)-b-POLY(4-NYLON) AND NANOPARTICLES THEREOF
[Problem] To provide a novel drug delivery system for γ-aminobutyric acid (GABA). [Solution] A block copolymer containing a poly(ethylene glycol) (or PEG) segment and a poly(GABA) (or Nylon 4) segment, and nanoparticles of the block copolymer. The nanoparticles are useful for preventing or treating depression.
The information processing device of the embodiment is provided with: a learning section that carries out learning of a machine learning model that inputs one or more non-polarized OCT images, which do not have polarization information and outputs pseudo-polarized OCT images that correspond to polarized OCT images, which have polarization information; and a storage unit for storing the learning results of the learning section.
A61B 3/10 - Appareils pour l'examen optique des yeux; Appareils pour l'examen clinique des yeux du type à mesure objective, c. à d. instruments pour l'examen des yeux indépendamment des perceptions ou des réactions du patient
This strain sensor for detecting surface strain comprises: a soft structure part provided with a pliable sheet and a plurality of protrusions having a prescribed height in a prescribed direction of the sheet, the protrusions being disposed with prescribed spacing on the sheet; and a strain gauge having a plurality of contact parts that respectively come into contact with the tops of the plurality of protrusions, the strain gauge deforming in conformance with changes in the spacing between the peaks caused by deformation of the sheet, and generating a change in electrical characteristics that corresponds to the deformation.
G01B 7/16 - Dispositions pour la mesure caractérisées par l'utilisation de techniques électriques ou magnétiques pour mesurer les déformations dans un solide, p.ex. au moyen d'une jauge de contrainte à résistance
The present invention relates to: an activity modulator which is a means for modulating the activity of CD300b-dependent phagocytosis; and medicine for the treatment or prevention of a disease or condition in which the activity is involved. The activity modulator comprises a CD300a-binding substance and modulates CD300b-dependent phagocytosis signals in a macrophage.
C07K 16/28 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
A61P 9/10 - Médicaments pour le traitement des troubles du système cardiovasculaire des maladies ischémiques ou athéroscléreuses, p.ex. médicaments antiangineux, vasodilatateurs coronariens, médicaments pour le traitement de l'infarctus du myocarde, de la rétinopathie, de l'insuffisance cérébro-vasculaire, de l'artériosclérose rénal
A61P 25/00 - Médicaments pour le traitement des troubles du système nerveux
A carbon nanotube-resin composite includes: a carbon nanotube assembled wire including a plurality of carbon nanotubes; and a resin, wherein in the carbon nanotube assembled wire, the carbon nanotubes are oriented at a degree of orientation of 0.9 or more and 1 or less.
D02G 3/02 - Filés ou fils caractérisés par la matière ou par les matières dont ils sont composés
D01F 9/127 - Filaments de carbone; Appareils spécialement adaptés à leur fabrication par décomposition thermique de gaz ou vapeurs d'hydrocarbures
D02G 3/40 - Filés dans lesquels les fibres sont réunies par des adhésifs; Filés ou fils imprégnés
H01B 1/24 - Matériau conducteur dispersé dans un matériau organique non conducteur le matériau conducteur comportant des compositions à base de carbone-silicium, du carbone ou du silicium
H01B 13/00 - Appareils ou procédés spécialement adaptés à la fabrication de conducteurs ou câbles
93.
HYDROPHILIC-HYDROPHOBIC COPOLYMER CARRYING SHORT CHAIN FATTY ACID ESTER
[Object]
[Object]
To provide a derivative of a short chain fatty acid that can exhibit physiological functions inherent in the short chain fatty acid.
[Object]
To provide a derivative of a short chain fatty acid that can exhibit physiological functions inherent in the short chain fatty acid.
[Solution]
[Object]
To provide a derivative of a short chain fatty acid that can exhibit physiological functions inherent in the short chain fatty acid.
[Solution]
Provided is a block or graft copolymer including a hydrophobic segment of a repeat unit containing a short chain fatty acid ester that is hydrolyzable by esterase in vivo and a hydrophilic segment including a poly(ethylene glycol) chain. These copolymers are effective in the treatment or therapeutic treatment of various diseases or disorders, including cancer.
C08F 293/00 - Composés macromoléculaires obtenus par polymérisation sur une macromolécule contenant des groupes capables d'amorcer la formation de nouvelles chaînes polymères rattachées exclusivement à une ou aux deux extrémités de la macromolécule de départ
C08G 65/26 - Composés macromoléculaires obtenus par des réactions créant une liaison éther dans la chaîne principale de la macromolécule à partir d'éthers cycliques par ouverture d'un hétérocycle à partir d'éthers cycliques et d'autres composés
C08G 65/334 - Polymères modifiés par post-traitement chimique avec des composés organiques contenant du soufre
NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY (Japon)
DAICO MFG CO., LTD. (Japon)
Inventeur(s)
Kumada, Hiroaki
Kitamura, Naoyuki
Nakamura, Tetsuyuki
Ikeda, Takeshi
Abrégé
As a sintered body for a radiation shielding material, which can effectively shield mainly low-energy-level neutrons, that is, thermal neutrons and lower, slow neutrons, and has excellent physical properties such as bending strength and Vickers hardness, leading to high machining strength, a sintered body for a radiation shielding material comprising LiF ranging between 99 wt. % to 5 wt. %, and one or more fluorides selected from among MgF2, CaF2, AlF3, KF, NaF, and/or YF3 ranging between 1 wt. % to 95 wt. %, having physical properties of a relative density of 92% or more, a bending strength of 50 MPa or more, and a Vickers hardness of 100 or more, is provided.
G21F 1/08 - Métaux; Alliages; Cermets, c. à d. mélanges frittés de céramiques et métaux
C04B 35/553 - Produits céramiques mis en forme, caractérisés par leur composition; Compositions céramiques; Traitement de poudres de composés inorganiques préalablement à la fabrication de produits céramiques à base de non oxydes à base de fluorures
C04B 35/626 - Préparation ou traitement des poudres individuellement ou par fournées
A method for inducing a hibernation-like state and a device for the same is described. The method is a chemical and physical method for reducing, in a subject, a theoretical set-point temperature of a body temperature and/or a feedback gain of heat production, or for inducing a hibernation-like state in the subject, the method including applying an excitatory stimulus to pyroglutamylated RFamide peptide (QRFP)-producing neurons. A device used to implement the method is also described.
A61N 1/36 - Application de courants électriques par électrodes de contact courants alternatifs ou intermittents pour stimuler, p.ex. stimulateurs cardiaques
A61N 1/05 - Electrodes à implanter ou à introduire dans le corps, p.ex. électrode cardiaque
A61M 21/02 - Autres dispositifs ou méthodes pour amener un changement dans l'état de conscience; Dispositifs pour provoquer ou arrêter le sommeil par des moyens mécaniques, optiques ou acoustiques, p.ex. pour mettre en état d'hypnose pour provoquer le sommeil ou la relaxation, p.ex. par stimulation directe des nerfs, par hypnose ou par analgésie
G01N 33/50 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique
[Problem] The present invention addresses the problem of discovering a molecule that is selectively expressed in mast cells and providing a prophylactic or therapeutic agent for allergic diseases. [Solution] This prophylactic or therapeutic agent is for allergic diseases and comprises an anti-Clec12b antibody or an antibody fragment thereof.
A61P 43/00 - Médicaments pour des utilisations spécifiques, non prévus dans les groupes
C07K 16/28 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
A carbon nanotube assembled wire includes a plurality of carbon nanotubes, wherein in a Raman spectrum of the carbon nanotube assembled wire, a ratio IB/IA of an integrated intensity IA in a range of a Raman shift of 120 cm−1 or more and 210 cm−1 or less and an integrated intensity IB in a range of a Raman shift of more than 210 cm−1 and 280 cm−1 or less is 0.1 or more.
The present invention provides a method for inducing a hibernation-like state and a device therefor. The present invention provides a method for reducing a theoretically set temperature for the body temperature of a subject and/or a feedback gain of heat production in the subject or a method for inducing a hibernation-like state in the subject, said method being a chemical and physical method that comprises applying an excitatory stimulation to a pyroglutamylated RF-amide peptide (QRFP) producing-neuron. The present invention also provides a device to be used for performing this method.
A61N 1/36 - Application de courants électriques par électrodes de contact courants alternatifs ou intermittents pour stimuler, p.ex. stimulateurs cardiaques
A61B 5/01 - Mesure de la température de parties du corps
A61B 5/083 - Mesure du taux de métabolisme en utilisant un essai respiratoire, p.ex. mesure du taux de consommation d'oxygène
99.
FRUIT-BEARING PLANT EXHIBITING HIGH TEMPERATURE RESISTANCE, HIGH YIELD, AND PARTHENOCARPY
The present application provides: a fruit-bearing plant exhibiting parthenocarpy or a potion thereof including a mutation in a Solyc10g038170 gene or ortholog thereof, the mutation causing deficiency or reduction in expression of a protein encoded by the Solyc10g038170 gene or ortholog thereof; a method for producing a parthenocarpic fruit-bearing plant or a potion thereof; and a method for selecting a parthenocarpic fruit-bearing plant or a potion thereof.
C12N 15/82 - Vecteurs ou systèmes d'expression spécialement adaptés aux hôtes eucaryotes pour cellules végétales
C12Q 1/6895 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p.ex. amorces ou sondes pour la détection ou l’identification d’organismes pour les plantes, les champignons ou les algues
C07K 14/415 - Peptides ayant plus de 20 amino-acides; Gastrines; Somatostatines; Mélanotropines; Leurs dérivés provenant de végétaux
NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY (Japon)
UNIVERSITY OF TSUKUBA (Japon)
Inventeur(s)
Iwata, Yasushi
Tomita, Kanako
Suzuki, Iwane
Morioka, Ryo
Yang, Tianjing
Abrégé
An artificial gene has a 15N abundance exceeding a natural abundance in bases of at least a portion of DNA. A method for mutating a gene includes a first step of producing a state in which 15N is unevenly distributed into a prescribed DNA in a living cell; and a second step of irradiation with a proton beam at an energy at which the 15N produces a resonant nuclear reaction.
brevets
